TO THE EDITOR Double minute chromosomes (dmins) have been reported in solid tumors, in the human myeloid cell line HL-60 and in 1-10% of patients with acute myeloid leukemia (AML). 1 All AML cases have been adults, predominantly elderly patients with leukemia of varying French-American-British (FAB) types.
2 C-MYC oncogene has been shown to be amplified in several but not all cases of AML with dmins and reported to be associated with chemotherapy resistance and disease aggressiveness. 3 It has also been suggested that AML patients with normal karyotype and numerous dmins might respond better to treatment and have a better prognosis than patients with complex karyotype and few dmins. 2 The role of C-MYC oncogene and relationship between dmins and other cytogenetic abnormalities in AML is poorly understood. 3 Dmins have been suggested to represent a sign of disease progression rather than a primary malignant event due to observations of concomitant occurrence of dmins and trisomy of chromosomes 4 or 6 although AML cases with dmins as a sole cytogenetic abnormality have been reported. 1, 2 Pseudo-Chediak-Higashi anomaly can be found in different forms of AML although they are most frequent in acute promyelocytic leukemia. AML cases with pink or purple pseudo-Chediak-Higashi anomaly, with or without simultaneous occurrence of Auer rods are seldom observed. 4 Electron microscopy of pseudo-Chediak-Higashi anomaly demonstrated that they are peroxidase positive granules with no obvious crystalline structure 4 some of which contain membranous lamellae and in some tubular structure can be observed. Chromosomal aberrations have been reported in some cases but there are no reports of the simultaneous occurrence of pseudo-Chediak-Higashi anomaly and dmins.
Three elderly male patients with AML M2 characterized by the occurrence of pseudo-Chediak-Higashi anomaly, presence of dmins as the only cytogenetic abnormality and by amplification of the C-MYC oncogene (8q24) are described (Table 1, Figures 1 and 2) . In case A, a 69-year-old retired engineer, referred to the hospital due to abdominal pain, swelling of the right leg, anemia and leukocytosis, was diagnosed with AML (M2) ( Table 1 ). The leukemic cells expressed CD117 and HLA-DR and were partly positive for CD11c and CD33. Physical examination was normal except for exhausted appearance. The swelling of the leg was found to be caused by iliac vein thrombosis. The patient had no history of exposure to common mutagenic or carcinogenic agents and no familial occurrence of hematological disorders. The patient received amsacrine 150 mg/m 2 daily for 5 days, plus etoposide 100 mg/m 2 and cytarabine 100 mg/m 2 daily for 5 days. Four weeks later, bone marrow smears showed partial remission with 5-6% blast cells and 10% abnormal monocytoid cells, a picture compatible with chronic myelomonocytic leukemia. A repeat bone marrow sample after 7 months of treatment with hydroxyurea was essentially unchanged showing 7-9% blast cells and a modest increase of monocytoid cells. Flow cytometric DNA histogram analysis revealed a hyperdiploid population with DNA index = 1.17. Hydroxyurea was stopped and the condition remained stable for 5 months. One year later the patient's condition deteriorated, bone marrow smears showed about 80% blast cells, and a course of cytotoxic therapy identical to the first course was given. The patient died 1 month later from infectious complications. At diagnosis cytogenetic analysis showed normal karyotype with presence of dmins ranging from 2 to 58 per cell, which were observed in 24 out of 30 metaphases (Table 1 In case B, a 60-year-old previously healthy policeman without heredity for blood disorders and a blood donor for 36 years, showed anemia at a routine blood bank check-up. He was diagnosed with AML M2 with surface marker expression of CD11c, CD15, CD33, CD117 and HLA-DR (Table 1, Figure 1 ). Weak positivity was also found for CD7. Physical examination was normal. He was treated with idarubicin 12 mg/m 2 daily for 3 days plus continuous infusions of cytarabine 200 mg/m 2 daily for 7 days. One month after commencing induction therapy the bone marrow showed partial remission. The patient needed two more induction courses to reach complete remission. Currently, he is on consolidation treatment 15 months after the diagnosis of AML. At diagnosis dmins were observed in four metaphases in bone marrow cell culture. Furthermore, two acentric fragments (ACE) were detected by G-banding in 21 out of 29 analyzed metaphases. Due to a small number of cells and poor quality of chromosomes, FISH analysis was performed on the same slide demonstrating C-MYC amplification in dmins and in the two acentric fragments.
In case C, a 73-year-old previously healthy male had transient abdominal pain a few weeks before diagnosis. Physical examination was normal but leukocytosis was found at routine laboratory investigation. He was on cobalamin treatment for pernicious anemia. There were no cases of hematological disorder in his family and he had no known exposure to mutagenic agents. He was diagnosed with AML M2 with the following immunophenotype: CD11c, CD13, CD33, CD34, CD117, HLA-DR and weak expression of CD7. He received idarubicin 12 mg/m 2 daily for 3 days plus continuous infusions of
Figure 2
Molecular cytogenetic analysis of bone marrow cells in case A (a-e) and in case C (f). (a) Fluorescence in situ hybridization with chromosome 8-specific probe revealed two chromosomes 8 and dmins. (b) Fluorescence in situ hybridization using locus-specific probe for C-MYC (8q24) (Oncor, Gaithersburg, MD, USA). The dmins showed C-MYC positive hybridization signal. (c-e) FISH was performed on metaphase chromosomes from bone marrow -case A, relapse. FISH using locus-specific probe for C-MYC (8q24) (c), WCP (Vysis, Downers Grove, IL, USA) probes for chromosomes 10 (d) and 18 (e) showed HSRs (C-MYC amplification) on chromosomes 10 and 18. (f) FISH was performed on metaphase chromosomes from bone marrow -case C, relapse. FISH using locus-specific probe for C-MYC (8q24) (Vysis) and WCP (Vysis) probe for chromosomes 9 showed HSRs (C-MYC amplification) on chromosome 9. 2 and cytarabine 100 mg/m 2 daily for 5 days. Bone marrow smears obtained 4 weeks later showed 5% blast cells, and was interpreted as remission. He was also treated with two consolidation courses and was in a good health until the leukemia relapsed 12 months after the initial diagnosis. The patient was again treated with ACE without any response and died of leukemia. At diagnosis dmins were detected by G-banding in four metaphases. FISH analysis of 48 metaphases with full-length probe for chromosome 8 and locus-specific probe for C-MYC demonstrated the presence of C-MYC oncogene in dmins and in 45 metaphases. When the leukemia had relapsed G-banding revealed a pseudodiploid karyotype and amplification of C-MYC locus was observed by FISH in the form of HSR on one of the chromosomes that was impossible to identify. After chemotherapy, the karyotype was 46,XY,−9,+mar. Besides two normal copies amplification of the C-MYC was detected on the marker chromosome which also contained material from chromosome 9 (Figure 2f) .
In the present study, the conspicuous findings were pseudo-Chediak-Higashi anomaly and double minutes chromosomes with C-MYC amplification in three patients diagnosed with AML M2. There was a response to standard induction treatment in all three cases, but complete remission was not achieved upon the first induction cycle in any of them. Conventional G-banding at diagnosis showed no evidence of karyotypic numerical abnormalities. In cases A and C the presence of dmins was the sole aberration and in case B dmins or two large extrachromosomal fragments were observed.
Dmins, frequently seen in solid tumors, are rare in hematological malignancies with a frequency occurrence from 3.3% to 10.6%. In a retrospective study including 30 000 specimens of hematological malignancies the presence of dmins was the sole cytogenetic abnormality in only 11 cases. 5 In our laboratory, dmins were observed in four out of 320 patients with AML, one with a complex karyotype and three with a normal karyotype who are reported here. Amplification of oncogenes such as BCL-2, C-ETS and MLL has been reported in patients with myeloproliferative disorders 6 although C-MYC amplification is more frequent. 7 Among previously reported AML M2/M4 cases with dmins, C-MYC was amplified in six. In the three cases reported here dmins represented C-MYC amplification. In one of the cases two large acentric DNA fragments and dmins were identified, both demonstrating C-MYC amplification. Thus, dmins and extrachromosomal fragments were functionally and structurally related. However, it is unknown if dmins generated episomes or if dmins appeared after breakage of extrachromosomal material. In two patients transition of C-MYC amplification from one form at diagnosis (dmins) to another form (HSRs) at relapse was observed. Dmins may have integrated into chromosomes 10 and 18 or into chromosome 9 in cases A and C, respectively, creating HSRs. C-MYC integration did not involve deletion of the 8q24 locus since normal signals were detected on both chromosome homologues. Also, it has been shown, that in promyelocytic cell line HL-60 dmins were present only at early passages with abnormally banded regions at later stages.
The cases reported here were morphologically characterized by pseudo-Chediak-Higashi anomaly in blast cells. In these patients C-MYC amplification in dmins represented a primary chromosomal abnormality since no other numerical or structural changes were detected at diagnosis. To our knowledge, this is the first report of sim-ultaneous finding of C-MYC amplification and pseudo-Chediak-Higashi. The concomitant occurrence of amplified C-MYC in dmins and pseudo-Chediak-Higashi anomaly in the same cells point to the possibility that C-MYC expression might have a pathophysiological role in the formation of pseudo-Chediak-Higashi anomaly in these cases.
It is known that amplified oncogenes can be eliminated from mammalian cell lines by low doses of hydroxyurea when present as extrachromosomal material but not when integrated. 8 Therefore, efforts to down-regulate C-MYC overexpression by decreasing the number of gene copies in HSRs could be worthwhile in future therapy of this type of AML. The prognostic significance of dmins remains unknown due to the small number of observations. The relationship between the number of dmins per cell, response to chemotherapy and outcome has not been studied. The patients in the present study required more than one induction course to achieve remission, lending some support to the opinion that dmins and possibly pseudo-Chediak-Higashi anomaly may be associated with chemotherapy resistance, disease progression and outcome. 3 In conclusion, our observations of simultaneous appearance of pseudo-Chediak-Higashi anomaly and double minutes (C-MYC) should draw attention of hematologists to this coincidence, which then might be regarded as causal.
